Photodynamic therapy (PDT) is a treatment modality that uses a photosensitizer, light, and oxygen to destroy abnormal cells. Verteporfin (CAS 129497-78-5) is a cornerstone photosensitizer, renowned for its efficacy in treating vascularized diseases, especially in the eye.

The fundamental Verteporfin mechanism of action involves its selective accumulation in rapidly proliferating tissues, such as the neovascular endothelial cells in conditions like wet age-related macular degeneration. Once administered and following a specific light exposure at 689 nm, Verteporfin absorbs light energy. This energy is transferred to molecular oxygen, generating reactive oxygen species (ROS), primarily singlet oxygen. These highly reactive ROS cause localized damage to the cellular membranes and organelles of the targeted abnormal blood vessels, leading to thrombosis and occlusion, thus halting disease progression.

Researchers seeking to advance PDT studies often need to buy Verteporfin from reliable sources. As a committed Verteporfin manufacturer, we ensure that our product is of the highest purity, which is critical for accurately elucidating the complex mechanisms involved in PDT. Understanding the compound's Verteporfin solubility in DMSO is also key for experimental design.

Our company provides Verteporfin to researchers worldwide, offering competitive pricing and consistent quality. By supplying high-grade Verteporfin, we aim to facilitate groundbreaking research into new PDT applications, whether for ophthalmological conditions or exploring its potential in oncology and other fields. Partner with us to access this vital research chemical and contribute to the future of targeted therapies.